Background: Detection of tumor cells in the blood, or minimal deposits in distant organs as bone marrow, could be important to identify cancer patients at high risk of relapse or disease progression. Quantitative polymerase chain reaction (PCR) amplification of tissue or tumor selective mRNA is the most powerful tool for the detection of this circulating or occult metastatic cells. Our study aims to identify novel gastrointestinal cancer-specific markers for circulating tumor cell detection. Method: Phase I preclinical study was performed by means of computational tools for expression analysis. In silico data were used to identify and prioritize molecular markers highly expressed in gastrointestinal cancers but absent in hematopoietic-derived libraries. Selected genes were evaluated by means of qRT-PCR in gastrointestinal cancer and hematopoietic cell-lines, normal human bone marrows and bloods, tumor tissue, and blood from cancer patients. Results: Novel and known mRNA markers for circulating tumor cell detection in gastrointestinal cancer have been identified. Among all the genes assessed, PKP3, AGR2, S100A16, S100A6, LGALS4, and CLDN3 were selected and assays based on blood qRT-PCR were developed. Reliably qRT-PCR assays for the novel targets plakophilin 3 (PKP3) and anterior gradient-2 (AGR2) to identify blood-borne cells in cancer patients were developed. Conclusions: Novel and known gastrointestinal-specific mRNA markers for circulating tumor cells have been identified through in silico analysis and validated in clinical material. qRT-PCR assay targeted to PKP3 and AGR2 mRNAs might be helpful to detect circulating tumor cells in patients with gastrointestinal cancer.
Introduction
Cancer of the gastrointestinal (GI) system encompasses a great proportion of tumor-related deaths in the world. Stage at the time of diagnostic and suitability for curative surgery remains the most important prognostic factors for digestive tract tumors. However, distant and loco-regional relapses frequently occur in spite of resection and adjuvant therapy. Colorectal cancer is the second leading cause of cancer deaths in the western countries. Most of these patients are diagnosed with localized disease, but their average 5-year survival is 50-60% in European countries [1] . For patients with other common GI malignancies, the options for curative resections are limited and survival remains poor, especially for esophageal and gastric carcinomas and pancreatic cancer.
Circulating tumor cells and occult metastasis (micrometastasis) are considered early stages in the progression of metastatic cascade in epithelial cancer. Detection of tumor cells in the blood or minimal deposits in distant organs as bone marrow could be important to identify patients at high risk of relapse or disease progression.
PCR amplification of tissue or tumor-selective mRNA is the most powerful tool for detection of this circulating or occult metastatic cells. Cytokeratin 20, carcinoembryonic antigen (CEA), and epidermal growth factor receptor (EGFR) are among the most frequent mRNA markers used in different reversetranscriptase polymerase-chain reaction (RT-PCR) assays in GI-cancer patients [ [2] , [3] ]. However, cancer genetic heterogeneity, down-regulation of mRNA marker in tumor cells, or low-level transcription of selected target in the hematopoietic compartment could compromise both sensitivity and specificity of molecular methods.
Selection of novel gastrointestinal cancer-specific transcripts and development of multi-marker quantitative RT-PCR assays are clearly outstanding research questions [ [4] , [5] ].
EGFR has been found to be overexpressed in a high proportion of gastrointestinal cancer and confers a poor prognosis [6] . Development of a quantitative assay to detect EGFR-expressing circulating tumor cells could be relevant for prognostic assessment, monitor response, or even thought select target therapy [7] .
RT-PCR assays for different glycosyltransferases have been developed for tumor cells detection in blood for breast cancer and melanoma patients [8] . Beta-1,6-N-acetylglucosaminyltransferase V (GNT-V, MGAT5; Hs.200/Mm.161; EC 4.1.155) expression in colorectal cancer had been correlated with metastasis and poor prognosis [9] . Thus GNT-V could represent a suitable mRNA biomarker for circulating tumor cell detection in gastrointestinal cancer patients.
The present study aims to identify novel GI cancer-specific markers for circulating tumor cells (CTC) detection. The development of mRNA-based tools for CTC biomarkers was done following the proposed guidelines of the Early Detection Research Network (EDRN) by the National Cancer Institute [10] . Phase I preclinical study was performed by means of computational tools for expression analysis. In order to validate the usefulness of this in silico approach to identify tumor cells markers, selected genes were evaluated in cell lines and clinical specimens. Finally, qRT-PCR assays for the novel targets plakophilin 3 (PKP3) and anterior gradient-2 (AGR2) to identifiy blood-borne cells in cancer patients were developed.
Materials and methods

Digital differential display and computational tools
Digital differential display (DDD) [11] is an in silico data-mining resource of the National Centre for Biotechnology Information (NCBI) for comparing sequence-based gene representation profiles. DDD is based on the UniGene concept and provides the genes that are represented at different levels in the selected cDNA libraries using statistical tests. DDD was used to identify molecular markers highly expressed in GI cancers but absent in blood and bone marrow-derived EST libraries. A set of cDNA libraries from blood and bone marrow (n = 13) was selected and it was compared with three pools of colon (n = 10), gastric (n = 13), and pancreatic (n = 5) carcinoma cDNA libraries. Each set was selected to include the broad heterogeneity of every tumor type and includes the minimum possible number of libraries generated from normalized or subtracted cDNAs.
Tags with statistically significant (p < 0.05; Fisher's exact test) higher expression in GI cancer libraries were detected and each EST was identified by UniGene cluster.
ESTs whose expression was 10 or more times higher in each set of cancer libraries in comparison with blood and bone marrow-derived EST libraries were selected. As a second filter step, we selected those tags with undetectable or low representation in hematopoietic control libraries, defined as an expression count equal or less than four in DDD output.
Furthermore, the tissue distribution and tumor specificity of every gene selected were analyzed using representation profiles obtained with virtual northern blot [VN, Ref. [12] ]. For each combination of tissue and pathologic status, VN shows a spot image representing the expression level of the selected gene and numeric columns. These represent the number of ESTs or SAGE tags corresponding to the gene divided by the total number of ESTs or SAGE tags in all libraries with the given tissue/histology. The statistical significance of the observed counts is measured using Bayesian analysis. Values (p) less or equal to 0.05 were considered significant [13] . Virtual northern blots for EGFR [14] and GNT-V [15] were also obtained. Functional data about the different gene selected were extracted from Gene Ontology (GO) annotations accessed in the Cancer Gene Anatomy Project (CGAP) database [ [12] , [16] ].
Cell lines
As a surrogated model of gastrointestinal cancer, the following human tumor cell-lines were used: colorectal carcinoma Gp5d, LoVo, DLD1, LS513, HT29, OJC4, OJC5, OJC6; gastric adenocarcinoma OE19, and pancreatic carcinoma OJC1. In addition, hematopoietic cell lines Jurkat, KG1, and K562 were analyzed.
The cell-lines OJC1, OJC4, OJC5, and OJC6 were developed in our laboratory from clinical specimens and they have been fully characterized [17] . All the cell lines were maintained in DMEM (Dulbecco's modified Eagle's medium-high glucose) and MegaCell™ RPMI-1640 mediums (both provided by Sigma-Aldrich) supplemented with 10% fetal calf serum inactivated, 1% penicillin, 1% streptomycin, and 1% amphotericin at 37 °C in 5% CO 2 . Cells from adherent cultures were recovered with 1% trypsin-1% EDTA cell dissociating reagent. Cell pellets from suspension cultures were obtained.
Clinical tissue specimens and blood preparation
Formalin-fixed and paraffin-embedded tissue (FFPE) from colon cancer specimens (n = 16) were obtained from the Pathology Department of the Juan Canalejo University Hospital. Array tissue apparatus, provided by Durviz, was used to obtain tissue cores with 2 mm diameter, selecting an area enriched for tumor tissue. These FFPE cores were used for specific mRNA detection of gene selected using DDD and computational tools.
Blood samples were prospectively collected from an additional cohort of gastrointestinal carcinoma patients (n = 11) and from age and sex matched non-carcinoma donors (n = 10). All the patients included were in the advanced stage, including eight colorectal cancer stage IV, one stage III rectal cancer before any treatment, and two pancreatic adenocarcinomas (stages II and IV). Blood were collected in 10 ml EDTA-containing tubes. To eliminate skin-plug contamination of the blood sample from initial venipuncture, the first several milliliters of blood were discarded. Samples were subjected to lysis and stabilized, in less than 1 h after blood withdrawal, in guanidinium-based RNA/DNA stabilization reagent for blood/bone marrow (Roche, Mannheim, Germany) at 10% (v/v) without cell and plasma separation. The mixtures were stored at −80 °C until mRNA extraction. Isolation reagent for blood and bone marrow (Roche, Mannheim, Germany) was used for mRNA extraction.
The study was approved by the Institutional Review Board of the Ethic Committee of Clinical Investigation of Galicia (Spain) and written informed consent was obtained from all patients.
RNA extraction and qRT-PCR
Isolation of total RNA from cell cultures was performed using High Pure RNA Isolation Kit (Roche, Mannheim, Germany) following manufacturer's instructions. From each cell line at 70% confluence, 10 6 cells were obtained for RNA isolation. Total RNA was treated with DNase I.
RNA isolation from FFPE tissue cores of each specimen was performed with Optimum™ FFPE RNA Isolation Kit (Ambion, Diagnostics); manufacturer's protocol was followed.
RNA isolated from human normal bone marrows were purchased from BD Biosciences-Clontech. Total RNA was derived from three different pools of normal human bone marrows (n = 23).
mRNA isolation from blood samples was performed with mRNA Isolation Kit for Blood/Bone Marrow (Roche, Mannheim, Germany), following manufacturer's recommendations. Briefly, total nucleic acid fraction was adsorbed to magnetic glass particle and poly(A)+ RNA was captured by using biotinlabeled oligo(dT) and streptavidin-coated magnetic particles. Each mRNA preparation was eluted in 12 μl RNase-free redistilled water. Purified poly (A)+ RNA was further processed in RT-PCR or stored at −80 °C until use. RNA integrity was confirmed by 2% agarose gel electrophoresis and stained with ethidium bromide.
cDNA synthesis
Reverse-transcription (RT) was performed from total cellular and bone marrow RNA using SuperScript™ First-Strand Synthesis System for RT-PCR (Invitrogen™, USA) up to a total volume of 20 μl × 1 μg of total RNA, 2.5 nM random hexamers, 0.5 mM dNTP mix, and 3 μl of DEPC-treated water were denatured at 65 °C for 5 min and chilled on ice for at least 1 min. On the other hand, 2 μl of 10× RT buffer, 5 mM MgCl 2 , 0.01 M DTT, and 40 U of RNaseOUT Recombinant Ribonuclease Inhibitor were mixed, collected by centrifugation, and incubated at 25 °C for 2 min. After incubation, 50 U of SuperScript™ RT) were added and incubated at 25 °C for 10 min, 42 °C for 50 min, and 70 °C for 15 min in a Thermocycler (Gene Amp PCR System 9700, Applied Biosystem). Finally, samples were chilled on ice and incubated with 2 U of RNAse H for 20 min at 37 °C before proceeding to amplification the target cDNA. For mRNA obtained from blood we follow the same procedure and 0.02 μg were subjected to cDNA synthesis. Positive and negative controls were included in each experiment. RNA extraction, reverse transcription-PCR assay setup, and post-reverse transcription-PCR product analysis were carried out in separate designated rooms to prevent cross-contamination. cDNA was quantified and assessed for purity using a GENIOUS UV spectrophotometer. cDNA concentration was measured at 260 nm. Also A260/A280 relation was calculated to know cDNA quality.
Quantitative real-time reverse transcription-PCR analysis
Real-time PCR analysis was performed, using primers and conditions shown in Table 1 We verified that amplifications and the expected size of each PCR product were specific. 1.8% agarose gel electrophoresis of all PCR products revealed a single band that corresponded to the singleamplified products as predicted by the melting curve analysis of the PCR. The amplification efficiency was determined for both target and housekeeping genes and was equal (99-100%).
PCR primers for mRNA amplification of the different selected genes were carefully designed using the web-based ProbeFinder software (Universal ProbeLibrary Design Center) [18] or via Roche Applied Science home page [19] . PCR primers have been positioned to span exon-intron boundaries, reducing the risk of detecting genomic DNA. Primers were purchased from Invitrogen™ (USA) and Roche (Mannheim, Germany).
Suitable selection of housekeeping gene(s) was performed using Human Endogenous Control Gene Panel (TATAA Biocenter, Sweden). The Excel macro GeNorm VBA applet for Microsoft Excel was used to determine the gene(s) with most correlated expression in the set of samples. Homo sapiens HPRT (Hypoxanthine-guanine phosphoribosyltransferase) were used as internal control for blood, bone marrow, and cell-lines samples. Also housekeeping gene was used to verify integrity of RNA and efficacy of reverse transcription. Any specimen with inadequate HPRT mRNA was excluded from the study.
Data analysis was performed with LigthCycler 480 Relative Quantification software (Roche, Mannheim, Germany). Relative levels of expression were calculated by the 2 −ΔΔCt method [20] . Each assay was done at least in triplicate and included marker-positive and marker-negative controls and reagent with no template controls.
DNA sequencing
At least one PCR product coming from each Real-time PCR experiment was used as template DNA. Products were purified by enzymatic method (ExoSAP-IT, Amersham USB). DNA sequencing was performed in a reference facility on ABI 3700 (Applied Biosystems) using Big Dye terminators. Forward and reverse primers used in sequencing reactions were the same as for the Real-time PCR, see Table 1 .
Statistical analysis
Statistical significance of differences was evaluated at the 95% confidence level by non-parametric statistic, Mann-Whitney U-test; p-value <0.05 were considered to be significant. Receiver operating characteristics (ROC) curve analysis was used to evaluate the diagnostic discrimination power of the selected differentially expressed genes. The threshold value for optimal sensitivity and specificity of PKP3 and AGR2 mRNA relative expression levels (R.E.L.) was also determined by ROC analysis. All of the statistical analyses were performed using the SPSS 12.0 for Windows.
Results
Search for gastrointestinal tumor-associated biomarkers using computational tools
Digital differential display (DDD) data were used to identify and prioritize molecular markers highly expressed in GI cancers but absent in blood and bone marrow-derived libraries. The pools used in this analysis, their ID libraries and the ESTs clustered are shown in Table 2 . Differential over representation were found for 34 genes in colorectal cancer libraries, for 96 in gastric cancer libraries, and for 144 in pancreatic cancer libraries in comparison with hematopoietic libraries. Potential up-regulated targets of note from this study include, among others, genes involved in cell adhesion and cytoskeleton, cell signaling, growth factor activity, ribosomal proteins, calcium-related metabolism, heat shock proteins as well as hypothetical proteins. From this set, we specifically selected those ESTs whose expression was at least 10-fold higher in each set of cancer libraries and undetectable or low represented in hematopoietic control libraries, defined as an expression count equal or less than four in DDD output. After these filters, we obtained a collection of 30, 58, and 91 genes in colon, gastric and pancreatic cancer-derived cDNA libraries, respectively ( Fig.  1 and Table 3 ). Among all of the up-regulated genes obtained, we identified several known genes which have previously been shown to be overexpressed in gastrointestinal tumors, and proposed as micrometastasis markers [21] as keratins 8, 18, and 19, CEACAM5, and tumor-associated calcium signal transducer 1 (TACSTD1). The tissue distribution and tumor specificity were analyzed using representation profiles obtained with virtual northern (Table 4) . Based on in silico data we could predict that some of the markers could be expressed in the hematopoietic compartment. Each column represents the number of ESTs or SAGE tags corresponding to the gene divided by the total number of ESTs or SAGE tags in all libraries with the given tissue/histology. Only SAGE data are available for white cells blood. PKP3, plakophilin 3; AGR2, anterior gradient homolog 2; LCN2, lipocalin 2 (oncogene 24p3); EFNB1, ephrin-B1; ASS1, argininosuccinate synthetase;
LGALS4; lectin, galactoside-binding, soluble, 4 (galectin 4); MGC3047, hypothetical protein, MXRA8; CLDN3, claudin 3; S100A16, S100 calcium binding protein A16; S100A6, S100 calcium binding protein A6 (calcyclin); GNT-V, beta-1,6-Nacetylglucosaminyltransferase V, MGAT 5; EGFR, epidermal growth factor receptor.
Experimental validation of the in silico data: qRT-PCR in cell lines
Criteria to select molecular markers identified by bioinformatic approach for quantitative real-time PCR studies are described in "Section 2.1". In brief, we select those novel markers with absent or low expression in blood and bone marrow-derived EST libraries and high expression in gastrointestinal cancer-derived EST libraries. In addition functional annotations based on Gene Ontology and related with epithelial cellular components or (potentially) with metastatic process [22] were taken into account.
In this way, we chose PKP3, AGR2, LCN2, S100A16, S100A6, EFNB1, ASS1, LGALS4, MGC3047/MXRA8, and CLDN3 for further experimental validation.
Interestingly PKP3, LGALS4, CLDN3, and EFNB1 were involved in cell adhesion, following biological process annotations in Gene Ontology. S100A6 and S100A16 are related in calcium-dependent protein binding. ASS1 has argininosuccinate synthase activity. No significantly overrepresented GO annotations were found for AGR2, LCN2 and MGC3047/MXRA8.
The expression of these selected markers was compared against EGFR and GNT-V, both described as overexpressed in gastrointestinal cancer. The expression levels of these genes were measured in 10 gastrointestinal tumor cell-lines (eight colorectal tumor cell-lines, one gastroesophageal cell-line, and one pancreatic cell-line). The values obtained were compared against three hematopoietic tumor cell-lines (Jurkat, K562, and KG1) and three different pools of normal bone marrow that include 23 individual samples. All selected genes assessed showed higher expression levels in gastrointestinal tumor cell-lines than in normal human bone marrow with two exceptions, LCN2 and MGC3047 (Fig. 2) . LCN2 showed lower expression levels in all gastrointestinal tumor cell-lines tested than normal human bone marrow. MGC3047 only showed higher expression levels over to those obtained with normal human bone marrow in OJC1 pancreatic tumor cell-line. The rest of the markers showed high expression in at least 7-10 gastrointestinal tumor cell-lines than in normal human bone marrow. Also, S100A16 was the unique marker assessed that showed higher expression levels than normal human bone marrow in all tumor celllines tested. Although GNT-V was expressed in 8 out of 10 cell digestive cancer cell-lines, its values were together with LCN2, EFNB1, ASS1, and MGC3047, the ones that showed the lowest expression in the tumor cell-lines assessed and they were not selected for blood mRNA quantification. Relative expression levels are shown in a color scale. Genes are described in Table 3 . Cell-lines (columns) are as shown: colorectal cancer (Gp5d, LoVo, DLD1, LS513, HT29, OJC4, OJC5, OJC6); gastric adenocarcinoma (OE19); pancreatic carcinoma (OJC1); hematopoietic (Jurkat, KG1 and K562); normal human bone marrows (BM). *Indicated those genes selected for their mRNA quantification in blood samples from patients.
Among all the genes assessed, PKP3, AGR2, S100A16, S100A6, LGALS4, and CLDN3 showed the most highly expression values with regard to normal human bone marrow.
mRNA quantitative detection of selected genes in peripheral blood from patients with gastrointestinal cancer and controls
We chose PKP3, AGR2, S100A6, S100A16, LGALS4, and CLDN3 for mRNA quantitative detection in peripheral blood samples from gastrointestinal cancer patients and controls. All of them showed an expression up to 10 2 -to 10 5 -fold higher in tumor cell-lines than in normal human bone marrow. Also, EGFR mRNA expression was measured in blood samples in order to compare their results with those obtained with the mRNA markers selected. All of these were expressed in at least 8 out of 10 tumor celllines.
Among the six potential molecular markers assessed in-patient and matched control blood samples, PKP3 and AGR2 showed the most remarkable results (Table 5 and Fig. 3 ). Values for PKP3 and AGR2 mRNA were significantly higher in blood samples from gastrointestinal cancer patients than in blood samples from non-carcinoma patients with a significant level of p = 0.000 and 0.019, respectively (MannWhitney U-test). mRNA levels were measured by qRT-PCR as described in Section 2. Results are the mean of at least three independent measurements. *There was no AGR2 expression in normal bloods. Fig. 3 . mRNA expression levels of PKP3, AGR2, LGALS4, CLDN3, S100A6, S100A16 and EGFR mRNA in peripheral blood: mRNA expression levels of PKP3, AGR2, LGALS4, CLDN3, S100A6, S100A16 and EGFR mRNA (Y-axis) determined in peripheral blood from non-carcinoma patients (C) and patients (P) with gastrointestinal cancer (X-axis). mRNA levels were measured by qRT-PCR as described in Section 2. Results are the mean of at least three independent measurements.
ROC curve analysis showed that the area under the ROC curve for PKP3 mRNA relative expression levels was 1.00 (S.E. = 0.00; p = 0.002). Optimal sensitivity (100%) and specificity (100%) was obtained by applying 56.61 as a PKP3 mRNA R.E.L. cutoff value.
In the case of AGR2, ROC curve analysis showed that the area under the ROC curve for AGR2 mRNA relative expression levels was 0.864 (S.E. = 0.092; 95% confidence range 0.683-1.045; p = 0.023). Optimal sensitivity (72.7%) and specificity (100%) was obtained by applying 0.044 as AGR2 mRNA R.E.L. cutoff value. In both cases, the calculated cutoff value may be useful to define positive or negative results and it discriminates samples of peripheral blood from patients with gastrointestinal cancer and control donors.
Area under the ROC curve for EGFR mRNA relative expression levels was 0.564 (S.E. = 0.151; 95% confidence range 0.268-0.859; p = 0.692). Thus, in our series, EGFR mRNA amplification was not useful to differentiate between carcinoma patients and controls. In relation to the other four potential molecular markers assessed, S100A6, S100A16, LGALS4, and CLDN3, neither of them could be considered specific enough to detect circulating tumor cells. Perhaps increasing the number of samples analyzed and ROC curve analysis, or using logistic regression to determine a combination equation using all six molecular markers assessed could yield a stronger and powerful diagnostic discrimination test.
PKP3 and AGR2 seem to be two new promising molecular markers for qRT-PCR detection of circulating tumor cells in peripheral blood samples from gastrointestinal cancer patients. Our findings had improved the previous results obtained with other common markers, widely used in micrometastasis detection, such as EGFR.
mRNA detection of selected genes in colon cancer samples
To validate the DDD data and the results obtained in cell-lines, we further investigated the mRNA expression of the genes PKP3, AGR2, LGALS4, and CLDN3 in colon cancer samples. These genes exhibited up-regulated expression based on both in silico data and GI cancer cell-lines qRT-PCR results. Absolute quantification by real-time RT-PCR analysis using RNA isolated from FFPE was used. Patient samples included primary colon tumors (n = 14). In addition metachronous metastatic lesions (hepatic and peritoneal) excised from two of these patients were studied.
Among all of the markers tested, CLDN3 showed expression in a large number of tissues analyzed (90.9%) followed by AGR2 (81.8%), LGALS4 (45.4%), and PKP3 (40%). For PKP3, there was no concordant mRNA expression between primary and metastasis in the cases studied, suggesting a dynamic regulation of their expression during tumor progression.
Discussion
Metastatic hematogenous spreading is one of the most important factors affecting the prognosis of carcinoma patients, including gastrointestinal cancer. Detection of carcinoma cells in the blood or minimal deposits in distant organs as bone marrow could be important to identify patients at high risk of relapse or disease progression [7] . PCR amplification of tissue or tumor-selective mRNA is the most powerful tool for surrogate detection of this isolated tumor cells. However, specificity of different mRNA-based assays has been controversial and there is a need for a systematic evaluation for each new biomarker proposed.
Our research aimed to identify, at first, a set of specific epithelial gene markers highly expressed in gastrointestinal cancer. Electronic databases analysis allowed us to obtain a list of genes that are differentially expressed, to the point of statistical significance, in colon, pancreas, and gastric libraries. We hypothesized that these transcripts could represent the molecular signature associated with CTC. Global gene expression profile of cancer cells isolated from blood has been recently described in colon, breast, and prostatic tumors, using an immunomagnetic enrichment and microarray analysis [23] . In a recent report, Solmi et al. [24] have used a microarray-based high-throughput screening method to identify candidate marker mRNAs for CTC detection. However, employing a conventional RT-PCR procedure they could not find a set of suitable and consistent mRNA marker for detection of colonic cells in the blood. In previous reports using both in silico data-mining tools and conventional RT-PCR, these authors [25] suggest that among 15 genes differentially expressed in colon, only non-SMC structural maintenance of chromosomes, element 1 protein (NSE1) and gastrin (GAS) mRNAs could be suitable for detection of circulating colon cancer cells in blood.
To point out the validity of our results using an in silico approach, our set of overexpressed genes included different markers previously used for CTC detection. In addition, AGR2 and different S100 proteins were identified in our work as well as in the CTC molecular profile proposed by Smirnov et al. [23] .
To obtain independent evidence to support the bioinformatics-approach for selecting CTC markers, quantitative mRNA expression of selected genes were analyzed in gastrointestinal cell-lines, hematopoietic cell-lines, and normal bone marrows. In order to validate their usefulness as potential molecular markers for gastrointestinal disseminated tumor cell detection, these results were compared with those obtained for EGFR and GNT-V.
Among all the genes assessed, PKP3, AGR2, S100A16, S100A6, LGALS4, and CLDN3 showed the most highly expressed values with regard to normal human bone marrow. For this reason they were chosen for further analysis for their expression in blood from gastrointestinal cancer patients and controls. One of the main problems with any mRNA-based assays is the illegitimate transcription of the so-called "epithelial specific transcripts" in hematopoietic compartment [ [2] , [3] , [4] ]. In our study, we included a quantitative RT-PCR approach and a significant number of controls samples (23 bone marrows and 10 bloods) in order to select the most specific mRNA markers.
In patient blood samples, qRT-PCR for PKP3 and AGR2 showed the most promising results. We could calculate an mRNA R.E.L. cutoff value of 56.61 and 0.044 for PKP3 and AGR2, respectively. These cut-off points may be useful to distinguish between samples of peripheral blood from gastrointestinal cancer patients and control samples. However, we need to underscore that all of the patients included in our series of blood samples were in advanced disease status. To better evaluate the predictive and prognostic role (if any) of PKP3 and AGR2 qRT-PCR assays in blood, a prospective study with a larger number, and less advanced, cancer patients are clearly needed.
When we compared our results obtained for PKP3 and AGR2 with those obtained for EGFR, our findings suggest that PKP3 and AGR2 could be better for its use as surrogate markers for circulating tumor cells detection in patients with GI cancer. This is the first time that PKP3, a member of the p120ctn/plakophilin subfamily of armadillo proteins, is suggested as a molecular marker for CTC detection. PKP3 is present in desmosomes of epithelial cells and binds all three desmogleins, desmocollin, plakoglobin, desmoplakin, and the epithelial keratin 18. This protein not only functions in desmosome-dependent cell adhesion, but in signaling transduction [ [26] , [27] , [28] ].
In view of the importance of β-catenin and other armadillo proteins in tumor biology, it is surprising that up to now, knowledge about the occurrence of PKPs in tumors is limited and little is known about their possible biologic role in tumor invasion and metastasis [29] . Recent studies had shown evidences that PKP3 protein may serve as useful marker for predicting the clinical outcome of head and neck tumors [30] and non-small cell lung cancer [31] . Other investigators [32] had demonstrated that this protein is highly expressed in various types of adenocarcinomas (colorectal, pancreatic, and prostate). In our work, PKP3 mRNA was highly expressed in digestive cancer cell-lines (8/10) but less in colon cancer samples (40%). One limitation of our analysis was the use of RNA isolated from FFPE. Recently, we studied PKP3 protein by immunohistochemistry in a large set of digestive tumors and found its expression in 66.7% of cases [33] . Aigner et al. have shown that PKP3 is repressed in the epithelial to mesenchymal transition of tumors under control by the E-cadherin repressor ZEB1 [34] . These data suggest, as previously stated [23] that gene expression signatures of CTCs may change as the disease progresses. In addition, selective suppression of gene transcription was one of the characteristics of the molecular signature associated with bone marrow micrometastasis in breast cancer [35] .
In relation with AGR2, the human homolog of Xenopus anterior gradient 2 (XAG2), our results corroborated and complemented a previous study in which it has been postulated as a marker for detection of circulating tumor cells in peripheral blood of advanced cancer patients [23] . AGR2 mRNA is expressed in several normal human tissue types that are rich in epithelial cells, including colon, pancreas, lung, stomach, rectum, prostate, and breast [ [36] , [37] , [38] ]. AGR2 has been demonstrated to be upregulated not only in hormonal-dependent tumors as breast, endometrial, renal, and prostate cancers but also in lung carcinomas [39] . Using qRT-PCR analysis, we demonstrated an increased AGR2 expression in gastrointestinal cancer cell-lines and colon tumors. Although AGR2 function is not known, experimental data suggest that it could act as a survival factor through inhibition of p53, and enhancing tumor cell adhesion to substratum [ [40] , [41] ].
However, identification of truly specific markers is a difficult task. Our quantitative RT-PCR assay demonstrated background expression in blood derived from non-tumor donors for S100A16, S100A6, LGALS4, and CLDN3. Although these gene transcripts were found highly expressed in cancer specimens, none of them could be considered specific enough, at first, for circulating epithelial cells detection. Their value in multigene qRT-PCR approach as a discrimination test could be analyzed using logistic regression and ROC curve.
In conclusion, novel and known gastrointestinal-specific mRNA markers for circulating tumor cells have been identified through in silico analysis and validated in clinical material. Our results indicate that quantitative real-time reverse transcription-PCR assay targeted to PKP3 and AGR2 mRNAs might be helpful to detect circulating tumor cells in patients with gastrointestinal cancer.
